



AHCL/ SE/ 42 /2019-20

November 7 2019

<b>The National Stock Exchange of India Limited</b> "Exchange Plaza", C-1, Block G Bandra-Kurla Complex, Bandra (E) Mumbai 400 051	<b>BSE Limited</b> Department of Corporate Services 1 <sup>st</sup> Floor, P.J. Towers, Dalal Street, Mumbai 400 001
<b>Symbol : AMRUTANJAN</b>	<b>Scrip Code: 590006</b>

Dear Sir / Madam,

**Sub: Outcome of the Board Meeting**

In terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR), we wish to inform that the Board of Directors of the Company at its meeting held today (**November 07, 2019**) had inter-alia:

- (i) Approved the Un-audited Financial Results for the quarter and half year ended September 30, 2019. The same along with the Limited Review Report issued by M/s. **BSR & Co. LLP**, Statutory Auditors of the Company is enclosed.
- (ii) Declared First Interim Dividend of Re. 0.55 per share for the financial year 2019-20 on the Equity Shares of the Company.

The Board Meeting commenced at 11.00 A.M. and concluded at 14:20 P.M. Request you to kindly take the same on record.

Thanking you,

Yours faithfully,

For Amrutanjan Health Care Limited



  
(M Srinivasan)

Company Secretary & Compliance Officer

**Encl:**

1. Un-audited Standalone Financials Results for the quarter and half year ended September 30 2019
2. Limited Review Report

**Amrutanjan Health Care Limited**

103, (Old No. 42-45), Luz Church Road,  
Mylapore, Chennai - 600 004  
Tamil Nadu, India.  
Tel : +91-44 - 2499 4465  
+91-44 - 2466 9000  
Fax : +91-44 - 2499 4585

E-mail : [customercare@amrutanjan.com](mailto:customercare@amrutanjan.com)  
Web Site : [www.amrutanjan.com](http://www.amrutanjan.com)  
Toll Free No. : 1 - 800 - 425 - 4545  
CIN - L24231TN1936PLC000017

**AMRUTANJAN HEALTH CARE LIMITED**  
CIN No : L24231TN1936PLC000017  
Registered Office: No. 103 (Old No. 42-45), Luz Church Road  
Mylapore, Chennai - 600 004

**Statement of Unaudited Financial Results for the quarter and six months ended 30 September 2019**

Particulars	Quarter ended			Period ended		
	30 September 2019 (Unaudited)	30 June 2019 (Unaudited)	30 September 2018 (Unaudited)	30 September 2019 (Unaudited)	30 September 2018 (Unaudited)	31 March 2019 (Audited)
						(Rs. in Lakhs)
<b>Continuing operations</b>						
<b>Income from operations</b>						
I Revenue from operations	7,480.77	4,459.59	6,204.90	11,940.36	9,781.74	25,322.73
II Other income	186.42	155.47	154.18	341.89	286.19	713.09
<b>III Total income (I + II)</b>	<b>7,667.19</b>	<b>4,615.06</b>	<b>6,359.08</b>	<b>12,282.25</b>	<b>10,067.93</b>	<b>26,035.82</b>
<b>IV Expenses</b>						
(a) Cost of materials consumed	2,427.56	1,684.04	2,206.28	4,111.60	3,949.65	9,052.32
(b) Purchases of stock-in-trade	1,103.91	829.62	659.87	1,933.53	1,145.09	3,164.07
(c) Changes in inventories of finished goods, work in progress and stock in trade	(136.13)	(72.07)	64.99	(208.20)	(365.17)	(329.54)
(d) Employee benefits expense	1,059.94	910.82	756.56	1,970.76	1,560.29	3,336.35
(e) Advertisement and selling expenditure	1,123.12	558.27	996.98	1,681.39	1,609.63	4,109.49
(f) Finance cost	5.03	5.19	3.57	10.22	5.36	8.22
(g) Depreciation and amortisation expense	126.66	84.95	80.54	211.61	152.39	315.97
(h) Other expenses	744.83	704.80	644.63	1,449.63	1,269.48	2,862.21
<b>Total expenses (IV)</b>	<b>6,454.92</b>	<b>4,705.62</b>	<b>5,413.42</b>	<b>11,160.54</b>	<b>9,326.72</b>	<b>22,519.09</b>
<b>V Profit before tax (III - IV)</b>	<b>1,212.27</b>	<b>(90.56)</b>	<b>945.66</b>	<b>1,121.71</b>	<b>741.21</b>	<b>3,516.73</b>
<b>VI Tax (benefit) / expenses</b>	<b>371.93</b>	<b>(20.08)</b>	<b>279.95</b>	<b>351.85</b>	<b>215.59</b>	<b>1,016.96</b>
<b>VII Profit after tax from continuing operations (V - VI)</b>	<b>840.34</b>	<b>(70.48)</b>	<b>665.71</b>	<b>769.86</b>	<b>525.62</b>	<b>2,499.77</b>
<b>Discontinued operations</b>						
Loss before tax from discontinued operations	-	-	(16.44)	-	(29.97)	(48.34)
Tax benefit	-	-	-	-	-	-
<b>VIII Profit / (loss) after tax from discontinued operations</b>	<b>-</b>	<b>-</b>	<b>(16.44)</b>	<b>-</b>	<b>(29.97)</b>	<b>(48.34)</b>
<b>IX Profit for the period (VII + VIII)</b>	<b>840.34</b>	<b>(70.48)</b>	<b>649.27</b>	<b>769.86</b>	<b>495.65</b>	<b>2,451.43</b>
<b>X Other comprehensive income</b>						
Re-measurement losses / gain on defined benefit plans, net of taxes	(31.48)	(2.43)	0.31	(33.91)	9.63	(56.55)
<b>Total other comprehensive income for the period</b>	<b>(31.48)</b>	<b>(2.43)</b>	<b>0.31</b>	<b>(33.91)</b>	<b>9.63</b>	<b>(56.55)</b>
<b>XI Total comprehensive income for the period (IX + X)</b>	<b>808.86</b>	<b>(72.91)</b>	<b>649.58</b>	<b>735.95</b>	<b>505.28</b>	<b>2,394.88</b>
<b>Paid-up equity share capital (Face value Re. 1/- each)</b>	<b>292.31</b>	<b>292.31</b>	<b>292.31</b>	<b>292.31</b>	<b>292.31</b>	<b>292.31</b>
<b>Earnings per equity share for continuing operations</b>						
Basic and diluted earnings per share	2.87 (not annualised)	(0.24) (not annualised)	2.28 (not annualised)	2.63 (not annualised)	1.80 (not annualised)	8.55 (annualised)
<b>Earnings per equity share for discontinued operations</b>						
Basic and diluted earnings per share	- (not annualised)	- (not annualised)	(0.06) (not annualised)	- (not annualised)	(0.10) (not annualised)	(0.17) (not annualised)

138



**AMRUTANJAN HEALTH CARE LIMITED**  
CIN No : L24231TN1936PLC000017  
Registered Office: No. 103 (Old No. 42-45), Luz Church Road  
Mylapore, Chennai - 600 004

**Notes:**

- The above financial results for the quarter and six months ended 30 September 2019 in respect of Amrutanjan Health Care Limited ('the Company') have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on 07 November 2019. The above results have been subjected to limited review by the statutory auditors of the Company. The auditors have issued an unmodified review report.
- The financial results has been prepared in accordance with recognition and measurement principles laid down in accordance with the Indian Accounting Standard ('Ind AS'), "Financial Reporting" as prescribed under Section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities Exchange Board of India ("SEBI") (Listing Obligations and Disclosure Requirements) Regulations 2015.
- The shareholders of the Company at its Annual General Meeting held on 25 September 2019, has approved final dividend of Rs. 1.05 per equity share of Re. 1 each for the financial year ended 31 March 2019.
- The Company has elected to exercise the option permitted under section 115BAA of the Income tax Act, 1961, as introduced by the Taxation laws (Amendment) Ordinance, 2019. Accordingly, the Company has recognised provision for income tax for the half year ended September 30, 2019 and re-measured its deferred tax assets basis the rate prescribed in the said section. The impact of above mentioned change has been recognised in the statement of profit and loss for the half year ended September 30, 2019.
- Segment reporting in the financial results:** Based on the 'management approach' as defined in Ind AS 108 "Operating Segments", the Chief Operating Decision Maker evaluates the Company's performance as OTC Products and Beverages.

Particulars	Quarter ended			Period ended		Year ended
	30 September 2019 (Unaudited)	30 June 2019 (Unaudited)	30 September 2018 (Unaudited)	30 September 2019 (Unaudited)	30 September 2018 (Unaudited)	31 March 2019 (Audited)
<b>1 Segment revenue</b>						
a OTC Products	7,158.78	3,549.72	5,870.31	10,708.50	8,683.00	23,073.35
b Beverages	244.82	854.02	296.45	1,098.84	1,024.86	2,075.98
c Others	77.17	55.85	38.14	133.02	73.88	173.40
<b>Total</b>	<b>7,480.77</b>	<b>4,459.59</b>	<b>6,204.90</b>	<b>11,940.36</b>	<b>9,781.74</b>	<b>25,322.73</b>
<b>2 Segment results</b>						
a OTC Products	1,206.66	(143.53)	1,029.70	1,063.13	1,035.97	3,645.74
b Beverages	(90.57)	8.58	(110.09)	(81.99)	(405.52)	(367.80)
c Others	(36.89)	(33.82)	(46.30)	(70.71)	(79.42)	(153.94)
<b>Total</b>	<b>1,079.20</b>	<b>(168.77)</b>	<b>873.31</b>	<b>910.43</b>	<b>551.03</b>	<b>3,124.00</b>
<b>Less :</b>						
i) Finance cost	5.03	5.19	3.57	10.22	5.36	8.22
ii) Other unallocable expenditure net of unallocable income	(138.10)	(83.40)	(75.92)	(221.50)	(195.54)	(400.95)
<b>Total profit before tax</b>	<b>1,212.27</b>	<b>(90.56)</b>	<b>945.66</b>	<b>1,121.71</b>	<b>741.21</b>	<b>3,516.73</b>
<b>3 Segment assets</b>						
a OTC Products	6,692.00	6,198.14	6,329.09	6,692.00	6,329.09	6,664.80
b Beverages	999.56	1,047.55	1,642.14	999.56	1,642.14	1,071.10
c Others	63.06	81.85	25.73	63.06	25.73	88.93
d Unallocated assets	12,151.44	10,915.52	8,599.25	12,151.44	8,599.25	10,936.51
<b>Total</b>	<b>19,906.06</b>	<b>18,243.16</b>	<b>16,596.21</b>	<b>19,906.06</b>	<b>16,596.21</b>	<b>18,761.34</b>
<b>4 Segment liabilities</b>						
a OTC Products	3,777.63	2,671.54	2,462.16	3,777.63	2,462.16	3,021.25
b Beverages	421.23	644.84	720.63	421.23	720.98	644.66
c Others	50.00	50.00	100.36	50.00	100.36	50.00
d Unallocated liabilities	717.63	376.06	241.05	717.63	241.05	471.80
<b>Total</b>	<b>4,966.49</b>	<b>3,742.44</b>	<b>3,524.55</b>	<b>4,966.49</b>	<b>3,524.55</b>	<b>4,187.71</b>
<b>Total capital employed in the Company</b>	<b>14,939.57</b>	<b>14,500.72</b>	<b>13,071.66</b>	<b>14,939.57</b>	<b>13,071.66</b>	<b>14,573.63</b>

6. Effective 1 April 2019, the Company adopted Ind AS 116 "Leases" and applied the standard to lease contracts existing on 1 April 2019 using modified retrospective approach. Accordingly, the comparatives for the year ended 31 March 2019 has not been retrospectively adjusted.

7. Pursuant to the amendment in SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in relation to submission of statement of cash flows for the half-year period with effect from 01 April 2019, the statement of cash flows for the half year ended 30 September 2019 has been presented in the table below. Considering that this is the first year of applicability of the aforesaid amendment, the comparative information has been provided for the previous year ended 31 March 2019.

8. During the earlier periods, the Company had decided to discontinue the operations of its Chemical division. Accordingly, the results for the comparative periods in this Statement have been revised to exclude the operations of the Chemical division. The results of the discontinued operations are presented below:

Particulars	Quarter ended			Period ended		Year ended
	30 September 2019 (Unaudited)	30 June 2019 (Unaudited)	30 September 2018 (Unaudited)	30 September 2019 (Unaudited)	30 September 2018 (Unaudited)	31 March 2019 (Audited)
I Total revenue	-	-	1.86	-	18.77	22.87
II Total expenses	-	-	18.30	-	48.74	71.21
III Loss before tax (I - II)	-	-	(16.44)	-	(29.97)	(48.34)
IV Tax benefit	-	-	-	-	-	-
V Loss from discontinued operations (III + IV)	-	-	(16.44)	-	(29.97)	(48.34)

For Amrutanjan Health Care Limited



S Sambhu Prasad  
Chairman & Managing Director

Date: 7 November 2019  
Place: Chennai





1. The first part of the document is a list of the names of the people who were present at the meeting.

2. The second part of the document is a list of the topics that were discussed.

3. The third part of the document is a list of the actions that were taken.

4. The fourth part of the document is a list of the conclusions that were reached.

5.



Handwritten signature or initials.



**AMRUTANJAN HEALTH CARE LIMITED**  
**CIN No : L24231TN1936PLC000017**  
Registered Office: No. 103 (Old No. 42-45), Luz Church Road  
Mylapore, Chennai - 600 004

**Statement of cash flows**

(Rs. in Lakhs)

Particulars	Six month ended 30 September 2019	Year ended 31 March 2019
	(Unaudited)	(Audited)
<b>Cash flow from operating activities</b>		
Profit / (loss) before income tax from:		
- Continuing operations	1,121.71	3,516.73
- Discontinued operation	-	(48.34)
Adjustments for:		
Depreciation and amortisation	211.61	325.59
Property, plant and equipment written off	-	25.50
Loss on sale of property, plant and equipment	-	3.07
Loss allowance on trade receivables	62.00	46.00
Change in fair value of investments		



24

*[Handwritten signature]*



# B S R & Co. LLP

Chartered Accountants

KRM Tower, 1<sup>st</sup> & 2<sup>nd</sup> Floor,  
No 1, Harrington Road, Chetpet,  
Chennai - 600 031, India.

Telephone : +91 44 4608 3100  
Fax : +91 44 4608 3199

## Limited Review Report

To  
Board of Directors of **Amrutanjan Health Care Limited**

1. We have reviewed the accompanying Statement of unaudited financial results of **Amrutanjan Health Care Limited** for the quarter ended and year to date results for the period from 01 April 2019 to 30 September 2019 ("the Statement").
2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

for **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No: 101248W/W-100022



**K Raghuram**  
Partner

Membership No: 211171

UDIN: 19211171AAAAEH9466

Place: Chennai

Date: 07 November 2019